eNauka - pregled

Pregled prema Projekat mAbxience Research

Prikaz rezultata 1 do 3 od 3
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2021Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G  ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan  ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas;
Garcia, Fernanda;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2020Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G  ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, CristinaKonferencijski rad
Mp kategorija će biti prikazana naknadno.
2021Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)Trukhin, Dmytro; ...; Andric, Zoran G  ; ...; (broj, koautora 19)Naučni članak
21aM21a - Vodeći međunarodni časopis kategorije M21a